The paper is proposed to explore the potential effects of Shufeng Jiedu Capsule against COVID-19. The ingredients and targets of Shufeng Jiedu Capsule were collected by the Traditional Chinese Medicine Systems Pharmac...The paper is proposed to explore the potential effects of Shufeng Jiedu Capsule against COVID-19. The ingredients and targets of Shufeng Jiedu Capsule were collected by the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP), and the gene names of potential targets were extracted by UniProtKB. Then we did protein-protein interaction networks functional enrichment analysis by the STRING platform, reconstructed drug-target pathways and networks to predict the likely protein targets of the capsule against COVID-19 with software Cytoscape 3.6.1, and carried out GO enrichment analysis and KEGG analysis with R 5.3.2 software. At last we validated our predictions on molecular docking. The results suggested that Shufeng Jiedu Capsule contained 155 ingredients and 237 targets, including 26 main active ingredients and 45 key targets. There were 2334 biological processes (BP), 103 cell composition (CC) and 198 molecular functions (MF) in GO Enrichment Analysis, and 177 pathways in the KEGG analysis. The molecular docking analysis showed that binding energy for 26 main active ingredients ranged from -32.21 to -25.94 kJ·mol-1, and the main targets bind to SARS-CoV-2 3CL hydrolase by acting on CASP9, PRKCA, RELA and others. Our study suggested that Shufeng Jiedu Capsule has potential therapeutic effects on COVID-19.展开更多
Objective:To systematically evaluate the efficacy and safety of Shufeng Jiedu Capsules in the treatment of acute attacks of chronic bronchitis.Methods:CNKI,VIP,CBM,WanFang,PubMed,EMbase,Cochrane Library and ChiCTR wer...Objective:To systematically evaluate the efficacy and safety of Shufeng Jiedu Capsules in the treatment of acute attacks of chronic bronchitis.Methods:CNKI,VIP,CBM,WanFang,PubMed,EMbase,Cochrane Library and ChiCTR were searched by computer,and randomized controlled trials of Shufeng Jiedu capsules in the treatment of AECB were integrated.The retrieval time was from the date of establishing the database to December 31,2020.Meta-analysis of outcome indicators[including effective rate,C-reactive protein(CRP),lung function[FEV1%and/or FEV1/FVC],interleukin-8(IL-8),tumor necrosis factor-α(TNF-α)]were carried out by RevMan 5.3 software,and the effective rate was tested by sequential analysis(TSA),and the quality of evidence was evaluated according to GRADE standards.Results:A total of 680 cases in 8 articles were included.Shufeng Jiedu Capsules improved the effective rate of clinicaltreatment[RR=1.20,95%CI(1.13,1.28)],improved lung function[FEV1:MD=0.33,95%CI(0.22,0.45),FEV1/FVC:MD=10.17,95%CI(8.15,12.19)],reduced CRP[MD=-7.32,95%CI(-8.42,-6.22)],IL-8[MD=-63.39,95%CI(-73.49,-53.29)],TNF-α[MD=-7.44,95%CI(-8.35,-6.53)]levels.The above differences were statistically significant(P<0.05),and no serious adverse reactions were reported in all studies.The results of TSA analysis showed that the experimental group had definite evidence for improving the efficiency.According to the GRADE evaluation system,the efficiency,TNF-αwere medium-quality evidences,FEV1 was low-quality evidence,and FEV1/FVC,CRP,and IL-8 were extremely low-quality evidence.Conclusions:The curative effect of Shufeng Jiedu capsule combined with western medicine in the treatment of AECB was better than that of single western medicine.Nevertheless,considering the limited sample size and the quality of included articles,higher quality RCTs are still needed to further confirm its effectiveness and safety.展开更多
Objective: To investigate the mechanism of Shufeng Jiedu Capsule(SJC) for treatment of COVID-19 based on network pharmacology. Methods: Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform ...Objective: To investigate the mechanism of Shufeng Jiedu Capsule(SJC) for treatment of COVID-19 based on network pharmacology. Methods: Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP) was used to obtain the active components and targets information of Polygoni Cuspidati Rhizoma Et Radix, Forsythiae Fructus, Istidis Radix, Radix Bupleuri, Herba Patriniae, Verbenae Herb, Phragmitis Rhizoma and licorice in SJC. The Genecards databases were used to obtain COVID-19 targets. The meridian tropisms of each herb in SJC were collected from ETCM Database.the proteins interations network were build by STRING database. The GO and KEGG pathways were analyzed by the computer R language. Results: SFC contains 8herbs, 176 compounds and the corresponding targets 237. 48 COVID-19 targets are treated by SJC. Such as IL-10, IL-6, PTGS1, PTGS2, GSK3B, STAT-1, IL-17 signaling pathway, HIF-1 signaling pathway, Toll-like receptor signaling pathway, T cell receptor signaling pathway and VEGF signaling pathway may be potential targets and signaling pathways for the prevention and treatment of COVID-19. Conclusion: The COVID-19 cantreatmented the potential targets and signaling pathways by the SJC, and play the role of antipyretic, anti-inflammatory, balance immunity, antiviral and so on. It will provide strong support for the later stage experiment and clinical application of SJC.展开更多
文摘The paper is proposed to explore the potential effects of Shufeng Jiedu Capsule against COVID-19. The ingredients and targets of Shufeng Jiedu Capsule were collected by the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP), and the gene names of potential targets were extracted by UniProtKB. Then we did protein-protein interaction networks functional enrichment analysis by the STRING platform, reconstructed drug-target pathways and networks to predict the likely protein targets of the capsule against COVID-19 with software Cytoscape 3.6.1, and carried out GO enrichment analysis and KEGG analysis with R 5.3.2 software. At last we validated our predictions on molecular docking. The results suggested that Shufeng Jiedu Capsule contained 155 ingredients and 237 targets, including 26 main active ingredients and 45 key targets. There were 2334 biological processes (BP), 103 cell composition (CC) and 198 molecular functions (MF) in GO Enrichment Analysis, and 177 pathways in the KEGG analysis. The molecular docking analysis showed that binding energy for 26 main active ingredients ranged from -32.21 to -25.94 kJ·mol-1, and the main targets bind to SARS-CoV-2 3CL hydrolase by acting on CASP9, PRKCA, RELA and others. Our study suggested that Shufeng Jiedu Capsule has potential therapeutic effects on COVID-19.
基金Inheritance and Innovation of TCM“Ten Million”Talent Project(Qihuang Project)(No.2019-QTL-003)。
文摘Objective:To systematically evaluate the efficacy and safety of Shufeng Jiedu Capsules in the treatment of acute attacks of chronic bronchitis.Methods:CNKI,VIP,CBM,WanFang,PubMed,EMbase,Cochrane Library and ChiCTR were searched by computer,and randomized controlled trials of Shufeng Jiedu capsules in the treatment of AECB were integrated.The retrieval time was from the date of establishing the database to December 31,2020.Meta-analysis of outcome indicators[including effective rate,C-reactive protein(CRP),lung function[FEV1%and/or FEV1/FVC],interleukin-8(IL-8),tumor necrosis factor-α(TNF-α)]were carried out by RevMan 5.3 software,and the effective rate was tested by sequential analysis(TSA),and the quality of evidence was evaluated according to GRADE standards.Results:A total of 680 cases in 8 articles were included.Shufeng Jiedu Capsules improved the effective rate of clinicaltreatment[RR=1.20,95%CI(1.13,1.28)],improved lung function[FEV1:MD=0.33,95%CI(0.22,0.45),FEV1/FVC:MD=10.17,95%CI(8.15,12.19)],reduced CRP[MD=-7.32,95%CI(-8.42,-6.22)],IL-8[MD=-63.39,95%CI(-73.49,-53.29)],TNF-α[MD=-7.44,95%CI(-8.35,-6.53)]levels.The above differences were statistically significant(P<0.05),and no serious adverse reactions were reported in all studies.The results of TSA analysis showed that the experimental group had definite evidence for improving the efficiency.According to the GRADE evaluation system,the efficiency,TNF-αwere medium-quality evidences,FEV1 was low-quality evidence,and FEV1/FVC,CRP,and IL-8 were extremely low-quality evidence.Conclusions:The curative effect of Shufeng Jiedu capsule combined with western medicine in the treatment of AECB was better than that of single western medicine.Nevertheless,considering the limited sample size and the quality of included articles,higher quality RCTs are still needed to further confirm its effectiveness and safety.
基金Scientific research project of Heilongjiang administration of traditional Chinese MedicineGeneral project of scientific research fund of Heilongjiang University of traditional Chinese Medicine(201819)
文摘Objective: To investigate the mechanism of Shufeng Jiedu Capsule(SJC) for treatment of COVID-19 based on network pharmacology. Methods: Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP) was used to obtain the active components and targets information of Polygoni Cuspidati Rhizoma Et Radix, Forsythiae Fructus, Istidis Radix, Radix Bupleuri, Herba Patriniae, Verbenae Herb, Phragmitis Rhizoma and licorice in SJC. The Genecards databases were used to obtain COVID-19 targets. The meridian tropisms of each herb in SJC were collected from ETCM Database.the proteins interations network were build by STRING database. The GO and KEGG pathways were analyzed by the computer R language. Results: SFC contains 8herbs, 176 compounds and the corresponding targets 237. 48 COVID-19 targets are treated by SJC. Such as IL-10, IL-6, PTGS1, PTGS2, GSK3B, STAT-1, IL-17 signaling pathway, HIF-1 signaling pathway, Toll-like receptor signaling pathway, T cell receptor signaling pathway and VEGF signaling pathway may be potential targets and signaling pathways for the prevention and treatment of COVID-19. Conclusion: The COVID-19 cantreatmented the potential targets and signaling pathways by the SJC, and play the role of antipyretic, anti-inflammatory, balance immunity, antiviral and so on. It will provide strong support for the later stage experiment and clinical application of SJC.
